Previous Close | 152.34 |
Open | 153.00 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1000 |
Day's Range | 152.75 - 155.45 |
52 Week Range | 105.56 - 175.91 |
Volume | |
Avg. Volume | 7,352,337 |
Market Cap | 270.615B |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | 21.97 |
EPS (TTM) | 6.97 |
Earnings Date | Jul 28, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | 5.64 (4.08%) |
Ex-Dividend Date | Apr 14, 2022 |
1y Target Est | 163.01 |
In the latest trading session, AbbVie (ABBV) closed at $153.14, marking a +0.53% move from the previous day.
The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.
AbbVie recently applied for FDA approval of its advanced Parkinson's disease drug candidate. This could be huge considering it's set to lose market exclusivity of Humira.